Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824627 · ClinicalTrials.gov registry record · Phase 2
Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
A Phase 2 study of Mood Disorder and Disruptive Behavior Disorders, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT02824627: Completed Phase 2 study of Mood Disorder and Disruptive Behavior Disorders, sponsored by University of Nebraska.
NCT02824627 is a Phase 2 study of Mood Disorder and Disruptive Behavior Disorders that has completed, run by University of Nebraska. The registered enrollment target is 58 participants, below the 1,299-participant average among 7 other Mood Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02824627, a Phase 2 study of Mood Disorder and Disruptive Behavior Disorders, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
Irritability and emotional dysregulation are recognized as serious aspects of psychopathology seen in in pediatric psychiatric patients. While various behavioral as well as psychopharmacological interventions have shown some efficacy in improving irritability and emotional dysregulation, there are no data determining the neurobiological mechanism of effect at the neural level. Previous studies have demonstrated that heightened amygdala response to negative emotional stimuli is closely related to irritability and emotional dysregulation in children and adolescents. Also, there are studies showing administration of oxytocin can decrease the heightened amygdala response to negative emotional stimuli across various psychiatric diagnoses. This study is a double-blind randomized trial of oxytocin for irritability and emotional dysregulation in the pediatric population. Neuroimaging modalities of fMRI and MEG are employed to probe the neuro-circuitry changes occurring as a result of the oxytocin intervention, specifically including heightened amygdala response to negative emotional stimuli and dysfunctional fronto-amygdala connectivity. The investigators will also investigate the genetic sequence of the oxytocin receptor in the study participants and its relationship with symptom profile and neural activity changes. Children and adolescents (age 10-18) with a diagnosis of disruptive mood and/or behavior disorders (including Attention Deficit/Hyperactivity Disorder \[ADHD\], Oppositional Defiant Disorder \[ODD\], Conduct Disorder \[CD\], and Disruptive Mood Dysregulation Disorder \[DMDD\]), and clinically significant levels of irritability and emotional dysregulation as measured by the Affective Reactivity Index Scale (score\>/= 4). 2 weeks randomized, double-blind treatment with intranasal oxytocin (24 IU daily, or 12 IU daily if the weight is \< 40kg) with assessment of diagnosis, symptom profiles (the Affective Reactivity Index \[ARI\], Inventory of Callous-Unemotional
Primary Outcome
The Affective Reactivity Index-Youth (ARI-Y) is a 7 item inventory (youth self-report) specifically designed to measure irritability and emotional dysregulation as a dimensional construct across psychopathologies in children and adolescents (Stringaris et al., 2012). ARI scores range from 0 to 12. Total scores are reported. Higher scores are indicative of more (worse) irritability. We report the change in ARI-Y score as our outcome measure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
Nebraska
- University of Nebraska Medical Center, Department of Psychiatry - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2021-08-10 |
| Phase | Phase 2 |
What the finished NCT02824627 record still lists
NCT02824627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,299-participant average among 7 other Mood Disorder trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Mood Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02824627 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT02824627 about?
NCT02824627 is a clinical study titled "Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders". Irritability and emotional dysregulation are recognized as serious aspects of psychopathology seen in in pediatric psychiatric patients. While various behavioral as well as psychopharmacological interventions have shown some efficacy in improving irritability and emotional dysregulation, there are n...
What is the current status of trial NCT02824627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-01-27. Estimated completion is 2021-08-10.
What conditions does trial NCT02824627 study?
This clinical trial studies the following conditions: Mood Disorder, Disruptive Behavior Disorders.
What interventions are being tested in trial NCT02824627?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02824627?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02824627 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
RECRUITING
-
Study of Premenstrual Syndrome and Premenstrual Dysphoria
RECRUITING
-
Adolescence, Puberty, and Emotion Regulation
COMPLETED
-
Perimenopause-Related Mood and Behavioral Disorders
COMPLETED
-
Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers
COMPLETED
-
Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI